Characterizing Fit-for-Purpose Real-World Data: An Assessment of a Mother–Infant Linkage in the Japan Medical Data Center Claims Database

References

• Brandon AR, Shivakumar G, Lee SC, Inrig SJ, Sadler JZ. Ethical issues in perinatal mental health research. Curr Opin Psychiatry. 2009;22(6):601–606. doi:10.1097/YCO.0b013e3283318e6f
   PubMed Web of Science ®Google Scholar
• Allesee L, Gallagher CM. Pregnancy and protection: the ethics of limiting a pregnant woman’s participation in clinical trials. J Clin Res Bioeth. 2011;2(108):1000108. doi:10.4172/2155-9627.1000108
   PubMedGoogle Scholar
• Margulis AV, Anthony M, Rivero-Ferrer E. Drug safety in pregnancy: review of study approaches requested by regulatory agencies. Curr Epidemiol Rep. 2019;6(3):380–389. doi:10.1007/s40471-019-00212-6
   Google Scholar
• Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–764. doi:10.1093/aje/kwv254
   PubMed Web of Science ®Google Scholar
• Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766–779. doi:10.1097/EDE.0b013e3181875e61
   PubMed Web of Science ®Google Scholar
• Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–75. doi:10.1016/j.jclinepi.2016.04.014
   PubMed Web of Science ®Google Scholar
• Daw JR, Hanley GE, Greyson DL, Morgan SG. Prescription drug use during pregnancy in developed countries: a systematic review. Pharmacoepidemiol Drug Saf. 2011;20(9):895–902. doi:10.1002/pds.2184
   PubMed Web of Science ®Google Scholar
• Feldman Y, Koren G, Mattice K, Shear H, Pellegrini E, MacLeod SM. Determinants of recall and recall bias in studying drug and chemical exposure in pregnancy. Teratology. 1989;40(1):37–45. doi:10.1002/tera.1420400106
   PubMedGoogle Scholar
• Agency for Healthcare Research and Quality (US). AHRQ methods for effective health care. In: Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for Evaluating Patient Outcomes: A User’s Guide. Agency for Healthcare Research and Quality (US); 2014.
   Google Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–337. doi:10.1016/j.jclinepi.2004.10.012
   PubMed Web of Science ®Google Scholar
• Krueger WS, Anthony MS, Saltus CW, et al. Evaluating the safety of medication exposures during pregnancy: a case study of study designs and data sources in multiple sclerosis. Drugs Real World Outcomes. 2017;4(3):139–149. doi:10.1007/s40801-017-0114-9
   PubMedGoogle Scholar
• Margulis AV, Andrews EB. The safety of medications in pregnant women: an opportunity to use database studies. Pediatrics. 2017;140(1):e20164194. doi:10.1542/peds.2016-4194
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Huybrechts KF, Chiu YH, Yland JJ, Bateman BT, Hernán MA. Emulating a target trial of interventions initiated during pregnancy with healthcare databases: the example of COVID-19 vaccination. Epidemiology. 2023;34(2):238–246. doi:10.1097/ede.0000000000001562
   PubMed Web of Science ®Google Scholar
• MotherToBaby. Critical periods of development. Organization of Teratology Information Specialists. Available from: https://mothertobaby.org/fact-sheets/critical-periods-development/pdf/. Accessed December, 2022.
   Google Scholar
• Palmsten K, Huybrechts KF, Mogun H, et al. Harnessing the Medicaid Analytic eXtract (MAX) to evaluate medications in pregnancy: design considerations. PLoS One. 2013;8(6):e67405. doi:10.1371/journal.pone.0067405
   PubMed Web of Science ®Google Scholar
• Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother–baby pairs in the German pharmacoepidemiological research database. Pharmacoepidemiol Drug Saf. 2011;20(3):258–264. doi:10.1002/pds.2038
   PubMed Web of Science ®Google Scholar
• Taylor LG, Thelus Jean R, Gordon G, Fram D, Coster T. Development of a mother–child database for drug exposure and adverse event detection in the military health system. Pharmacoepidemiol Drug Saf. 2015;24(5):510–517. doi:10.1002/pds.3759
   PubMed Web of Science ®Google Scholar
• Andrade SE, Toh S, Houstoun M, et al. Surveillance of medication use during pregnancy in the mini-sentinel program. Maternal Child Health J. 2016;20(4):895–903. doi:10.1007/s10995-015-1878-8
   PubMed Web of Science ®Google Scholar
• Andrade SE, Davis RL, Cheetham TC, et al. Medication exposure in pregnancy risk evaluation program. Matern Child Health J. 2012;16(7):1349–1354. doi:10.1007/s10995-011-0902-x
   PubMed Web of Science ®Google Scholar
• Moore Simas TA, Huang M-Y, Packnett ER, Zimmerman NM, Moynihan M, Eldar-Lissai A. Matched cohort study of healthcare resource utilization and costs in young children of mothers with postpartum depression in the United States. J Med Econ. 2020;23(2):174–183. doi:10.1080/13696998.2019.1679157
   PubMed Web of Science ®Google Scholar
• Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf. 2013;22(1):16–24. doi:10.1002/pds.3284
   PubMed Web of Science ®Google Scholar
• Yusuf A, Chia V, Xue F, Mikol DD, Bollinger L, Cangialose C. Use of existing electronic health care databases to evaluate medication safety in pregnancy: triptan exposure in pregnancy as a case study. Pharmacoepidemiol Drug Saf. 2018;27(12):1309–1315. doi:10.1002/pds.4658
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Obara T, Jin K, et al. Folic acid prescribed to prenatal and postpartum women who are also prescribed antiepileptic drugs in Japan: data from a health administrative database. Birth Defects Res. 2020. doi:10.1002/bdr2.1748
   PubMedGoogle Scholar
• Ishikawa T, Obara T, Nishigori H, et al. Antihypertensives prescribed for pregnant women in Japan: prevalence and timing determined from a database of health insurance claims. Pharmacoepidemiol Drug Saf. 2018;27(12):1325–1334. doi:10.1002/pds.4654
   PubMed Web of Science ®Google Scholar
• Andrade SE, Bérard A, Nordeng HME, Wood ME, van Gelder MMHJ, Toh S. Administrative claims data versus augmented pregnancy data for the study of pharmaceutical treatments in pregnancy. Curr Epidemiol Rep. 2017;4(2):106–116. doi:10.1007/s40471-017-0104-1
   PubMedGoogle Scholar
• Daniel G, Silcox C, Bryan J, McClellan M, Romine M, Frank K. Characterizing RWD quality and relevancy for regulatory purposes; 2022.
   Google Scholar
• Berger M, Daniel G, Frank K, et al. A framework for regulatory use of real-world evidence. White paper prepared by the Duke Margolis Center for Health Policy. 2017:6.
   Google Scholar
• Noh Y, Yoon D, Song I, Jeong HE, Bae JH, Shin J-Y. Discrepancies in the evidence and recommendation levels of pregnancy information in prescription drug labeling in the United States, United Kingdom, Japan, and Korea. J Womens Health. 2018;27(9):1086–1092. doi:10.1089/jwh.2017.6792
   Web of Science ®Google Scholar
• Little SH, Motohara S, Plegue M, Medaugh C, Sen A, Ruffin MT. Japanese women’s concerns and satisfaction with pregnancy care in the United States. J Perinat Educ. 2020;29(3):152–160. doi:10.1891/j-pe-d-19-00009
   PubMed Web of Science ®Google Scholar
• Ruggles BM, Xiong A, Kyle B. Healthcare coverage in the US and Japan: a comparison. Nursing. 2019;49(4):56–60. doi:10.1097/01.NURSE.0000553277.03472.d8
   PubMedGoogle Scholar
• Hornbrook MC, Whitlock EP, Berg CJ, et al. Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system. Health Serv Res. 2007;42(2):908–927. doi:10.1111/j.1475-6773.2006.00635.x
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Protocol for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD); 2020.
   Google Scholar
• Japan Ministry of Health Labour and Welfare. Vital statistics of Japan, final data natality. Available from: https://www.e-stat.go.jp/en. Accessed October, 2021.
   Google Scholar
• Ishikawa T, Oyanagi G, Obara T, et al. Validity of congenital malformation diagnoses in healthcare claims from a University Hospital in Japan. Pharmacoepidemiol Drug Saf. 2021;30(7):975–978. doi:10.1002/pds.5244
   PubMed Web of Science ®Google Scholar
• Kim HM, Smith EG, Stano CM, et al. Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use. BMC Health Serv Res. 2012;12(1):18. doi:10.1186/1472-6963-12-18
   PubMed Web of Science ®Google Scholar
• Desai RJ, Solomon DH, Shadick N, Iannaccone C, Kim SC. Identification of smoking using medicare data — a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf. 2016;25(4):472–475. doi:10.1002/pds.3953
   PubMed Web of Science ®Google Scholar
• Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39(12):1518–1534. doi:10.1177/0333102419851855
   PubMed Web of Science ®Google Scholar
• Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17(1):15–22. doi:10.1046/j.1468-2982.1997.1701015.x
   PubMed Web of Science ®Google Scholar
• Sakai F, Hirata K, Igarashi H, et al. A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan. J Headache Pain. 2022;23(1):70. doi:10.1186/s10194-022-01439-3
   PubMed Web of Science ®Google Scholar
• Kusunoki T, Morimoto T, Nishikomori R, et al. Changing prevalence and severity of childhood allergic diseases in Kyoto, Japan, from 1996 to 2006. Allergol Int. 2009;58(4):543–548. doi:10.2332/allergolint.09-OA-0085
   PubMedGoogle Scholar
• Fukutomi Y, Taniguchi M, Watanabe J, et al. Time trend in the prevalence of adult asthma in Japan: findings from population-based surveys in Fujieda City in 1985, 1999, and 2006. Allergol Int. 2011;60(4):443–448. doi:10.2332/allergolint.10-OA-0282
   PubMedGoogle Scholar
• Rothman KJ, Greenland S. Planning study size based on precision rather than power. Epidemiology. 2018;29(5):599–603. doi:10.1097/ede.0000000000000876
   PubMed Web of Science ®Google Scholar
• Cooper WO, Hernandez-Diaz S, Gideon P, et al. Positive predictive value of computerized records for major congenital malformations. Pharmacoepidemiol Drug Saf. 2008;17(5):455–460. doi:10.1002/pds.1534
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Obara T, Nishigori H, et al. Development of algorithms to determine the onset of pregnancy and delivery date using health care administrative data in a University Hospital in Japan. Pharmacoepidemiol Drug Saf. 2018;27(7):751–762. doi:10.1002/pds.4444
   PubMed Web of Science ®Google Scholar
• Khoury MJ, Flanders WD, James LM, Erickson JD. Human teratogens, prenatal mortality, and selection bias. Am J Epidemiol. 1989;130(2):361–370. PMID: 2750731. doi:10.1093/oxfordjournals.aje.a115342
   PubMed Web of Science ®Google Scholar
• Grzeskowiak LE, Gilbert AL, Morrison JL. Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy. Eur J Clin Pharmacol. 2012;68(5):459–467. doi:10.1007/s00228-011-1154-9
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Rasmussen SA, Friedman JM; Study NBDP. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011;51(2):264–270. doi:10.1177/0091270010373928
   PubMed Web of Science ®Google Scholar